Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
29 hedge funds and large institutions have $8.59M invested in Talis Biomedical Corporation Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 12 closing their positions.
17% less funds holding
Funds holding: 35 → 29 (-6)
29% less capital invested
Capital invested by funds: $12.1M → $8.59M (-$3.51M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$24.5K |
| 2 |
Man Group
London,
United Kingdom
|
+$11K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.54K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$468 |
| 5 |
LFG
Larson Financial Group
St Louis,
Missouri
|
+$164 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.37M |
| 2 |
NM
Newtyn Management
New York
|
-$231K |
| 3 |
Morgan Stanley
New York
|
-$77.8K |
| 4 |
Renaissance Technologies
New York
|
-$63.7K |
| 5 |
Millennium Management
New York
|
-$61.2K |
TLIS Hedge Fund Activity: Q3 2022 in Review
29 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q3 2022, worth a combined $8.59M — down 29% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TLIS and 6 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, opening a new position worth an estimated $24.5K. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $1.37M.
- 29 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q3 2022, down from 35 in Q2 2022.
- Funds reported $8.59M of Talis Biomedical Corporation Common Stock stock for Q3 2022, down 29% quarter-over-quarter.
- 6 funds opened new Talis Biomedical Corporation Common Stock positions in Q3 2022 and 12 closed out, a net change of -6 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q3 2022 was Jane Street, an estimated $24.5K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q3 2022 was ArrowMark Colorado Holdings, an estimated $1.37M sold.
Based on aggregated 13F filings for Q3 2022.